Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

ed for the treatment of a serious or life-threatening condition and that it has the potential to address unmet medical needs for the condition. Virulizin(R) is a registered trademark owned by Lorus Therapeutics Inc.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors cou
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... PLYMOUTH, Minn., Dec. 15 The Mosaic Company (NYSE: ... quarter fiscal year 2010 earnings results and financial tables ... trading on the New York Stock Exchange. Results ... ,, The Company will host a conference call ... discuss the results. The call will begin at ...
(Date:12/15/2009)... On January 20th, 2010, the inaugural ... Publication Professionals (ISMPP) will be held at the ... than 100 attendees are expected at this prestigious ... editors, publishers, medical writers and medical agencies to ... the impact of guidelines and regulations such as ...
(Date:12/15/2009)... Prinz Law Office has announced the launch of several ... secure legal services in the current economic climate. ... the opportunity to finance legal services over a period ... any equity in their start-up companies. The second ... fixed montly payment arrangements over 6 to 12 month ...
(Date:12/14/2009)... Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic") announced ... The Scripps Research Institute ("Scripps") by entering into ... of Dyadic,s patented and proprietary C1 fungus ("C1"). ... successful relationship between the two organizations which began ... annotate the C1 genome for the first time. ...
Breaking Biology Technology:Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5
... (NYSE: BSX ) will webcast its conference call ... 2008 on Tuesday,July 22, at 8:30 a.m. ET., ... and Chief Executive,Officer, and Sam Leno, Executive Vice President ... replay of this call will be available at, http://www.bostonscientific.com ...
... Pandemic Planning -, NUTLEY, N.J., June 26 ... that will allow U.S. businesses,to maintain access to their ... with limited upfront investment and more adaptability,to deal with ... new plan, businesses pay a nominal annual fee to ...
... the Spread of Pancreatic ... ... president and chairman of the Pharmaceutical Research Institute (PRI),at Albany College of ... Institute, part of the National Institutes,of Health. Dr. Mousa along with a ...
Other Biology Technology:Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results 2Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 2Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 3Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 4Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R) 5Albany College of Pharmacy Researcher Receives $368,445 Grant from the National Institutes of Health 2
(Date:12/14/2009)... of the proteins in a species of salamander that ... similar regeneration could be induced in humans. , ... University Indianapolis and colleagues investigated over three hundred proteins ... salamander that has the unique natural ability to regenerate ... that this knowledge will contribute to a better understanding ...
(Date:12/14/2009)... defining feature of humans. That,s until examples of tool use ... array of other mammals. Now, a report in the December ... publication, adds an octopus to the growing list of tool ... trick that the researchers call stilt walking. In it, the ... makes its eight arms rigid, and raises the whole assembly ...
(Date:12/14/2009)... good as laparoscopy is in preventing some of the stresses ... including reduced blood flow and organ dysfunction. Laparoscopy is a ... , By adding another gas to ... laparoscopy, researchers at Duke University Medical Center have found they ... , The gas ethyl nitrite (ENO) helped to open blood ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2Tool use in an invertebrate: The coconut-carrying octopus 2Gas improves blood flow and organ status during minimally invasive surgery 2New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Unt 57524 1New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Unt 57524 2New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Unt 57524 3New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Unt 57524 4New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Unt 57524 5Appeals Court Rules in Favor of Prometheus Upholds the Patentability of Its Claims for Methods of Thiopurine Metabolite Testing 57519 1Appeals Court Rules in Favor of Prometheus Upholds the Patentability of Its Claims for Methods of Thiopurine Metabolite Testing 57519 2Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Associations Family Link Program In Connecticut 57514 1Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Associations Family Link Program In Connecticut 57514 2Anthem Blue Cross and Blue Shield Foundation Grant Supporting American Diabetes Associations Family Link Program In Connecticut 57514 3
... Physicians apparently learn to shut off the portion of their ... while treating them and instead activate a portion of the ... brain scans at the University of Chicago. , Because ... part of the healing process, they also must develop the ...
... Americans remain pessimistic about the state of the environment ... according to the second annual ,America,s Report Card on ... Woods Institute for the Environment at Stanford University in ... pessimism and general desire for action has remained constant ...
... might affect the type and evolution of toxins in their ... Evolutionary Biology shows. , In snakes, venom composition varies ... feed on a range of animals and birds, so scientists ... in their venom. Sea snakes, on the other hand, tend ...
Other Biology News:Doctors learn to control their own brains' pain responses to better treat patients 2Doctors learn to control their own brains' pain responses to better treat patients 3Americans remain pessimistic about the environment, Stanford-AP survey finds 2Americans remain pessimistic about the environment, Stanford-AP survey finds 3Americans remain pessimistic about the environment, Stanford-AP survey finds 4
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
... converts Cap 0 (or Cap 0-like) RNA ... structure has been shown to increase in ... This improvement is seen in Cap 0 ... System as well as those Cap 0 ...
Form: Ready to use Applications: ELISA...
Form: Ready to use Applications: ELISA...
Biology Products: